Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study" [Thromb. Res. vol. 185, January 2020, pages 13-19]
Thromb Res. 2020 Jul:191:156-159.
doi: 10.1016/j.thromres.2020.02.022.
Epub 2020 Mar 6.
1 Department of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: f.i.mulder@amsterdamumc.nl.
2 Department of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
3 Department of Medicine and Ageing Sciences, University G. D'Annunzio, Chieti, Italy.
4 Ottawa Hospital Research Institute, Ottawa, Canada.
5 Daiichi Sankyo Pharma Development, Basking Ridge, NJ, USA.
6 Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, USA.
7 Department of Medicine, Division of Hematology, University of Washington, Seattle, USA.
8 Thrombosis Research Institute, University College London, London, United Kingdom.
9 Department of Hematology, Middlemore Hospital, Auckland, New Zealand.
10 ITREAS, Academic Research Organization, Amsterdam, the Netherlands.
11 Department of Hematology, Queen Elizabeth II Health Sciences Centre, Halifax, Canada.
12 Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium.
13 Department of Internal Medicine, Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, USA.
14 McMaster University, The Thrombosis and Atherosclerosis Research Institute, Hamilton, Canada.
15 University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City, USA.